Harrow, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Harrow, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $1.08M, a 955.88% increase year-over-year.
- Harrow, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $25.00K, a 8.70% increase year-over-year.
- Harrow, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $162.00K, a 66.53% decline year-over-year.
- Harrow, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $102.00K, a 41.04% decline year-over-year.
- Harrow, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $85.00K, a 54.55% increase from fiscal 2022.
- Harrow, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $55.00K.
- Harrow, Inc. stock issued during period, value, stock options exercised for fiscal 2016 was $55.00K.
- Harrow, Inc. stock issued during period, value, stock options exercised for fiscal 2014 was $584.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $1.08M 10-Q · filed 2026-08-10 | |
| 2026-03-31 | $25.00K 10-Q · filed 2026-05-11 | |
| 2025-09-30 | $162.00K 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $102.00K 10-Q · filed 2026-08-10 | |
| 2025-03-31 | $23.00K 10-Q · filed 2026-05-11 | |
| 2024-09-30 | $484.00K 10-Q · filed 2025-11-10 | $1.00M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $173.00K 10-Q · filed 2025-08-11 | $539.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $348.00K 10-Q · filed 2025-05-08 | $451.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $85.00K 10-K · filed 2026-03-02 |
| 2023-09-30 | $18.00K 10-Q · filed 2023-11-13 | $299.00K derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-06-30 | $85.00K 10-Q · filed 2024-08-07 | $281.00K derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $148.00K 10-Q · filed 2023-05-11 | $199.00K derived: sum of 4 quarters · filed 2024-03-19 |
| 2022-12-31 | $48.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $55.00K 10-K · filed 2024-03-19 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | |
| 2022-06-30 | $3.00K 10-Q · filed 2023-08-09 | |
| 2022-03-31 | $4.00K 10-Q · filed 2023-05-11 | |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $55.00K 10-K · filed 2018-03-08 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | |
| 2016-03-31 | $55.00K 10-Q · filed 2016-05-12 | |
| 2014-12-31 | $189.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-23 | $584.00K 10-K · filed 2016-03-23 |
| 2014-09-30 | $137.20K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | |
| 2014-06-30 | $115.76K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-13 | |
| 2014-03-31 | $330.85K 10-Q · filed 2014-05-15 | |
| 2012-12-31 | $800.00 10-K · filed 2013-03-18 | |
| 2009-12-31 | $49.50K 10-K · filed 2013-03-18 | |
| 2007-12-31 | $250.00 10-K · filed 2013-03-18 | |
| 2005-12-31 | $100.00 10-K · filed 2014-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |